GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an ...

GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects a multi-blockbuster ...

GSK Pharmaceuticals India focuses on affordable general medicine access amidst premiumisation trend, discussed by managing ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Curevac N.V. ( (CVAC) ) has released its Q3 earnings. Here is a breakdown of the information Curevac N.V. presented to its investors. CureVac ...

23andMe's big push into drug development, announced with great fanfare almost a decade ago, has ended with a whimper and ...

Detailed price information for 23Andme Holding Co. (ME-Q) from The Globe and Mail including charting and trades.

We were delighted to welcome over 100 guests to International Men’s Day at Stevenage Bioscience Catalyst. As part of our ...